News

Filter

BioRestorative Therapies enters research accord with Pfizer

22-05-2014

US stem-cell therapies developer BioRestorative Therapies has entered into a two-year collaborative research…

BioRestorative TherapiesBiotechnologyLicensingMetabolicsPfizerResearch

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

Forest Labs and Glenmark collaborate; Takeda and Amylin cancel obesity accord

27-12-2012

Indian drugmaker Glenmark Pharmaceuticals has entered into an agreement with Forest Laboratories (NYSE:…

AmylinBiotechnologyBristol-Myers SquibbForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingMetabolicsmetreleptinNeurologicalPharmaceuticalpramlintideResearchTakeda Pharmaceuticals

AstraZeneca aligns with Regulus for microRNA therapeutics

16-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended

03-07-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

Anchor Thera to sell rights to cancer, metabolic disease drug candidates to Johnson & Johnson unit for $480 million

10-09-2010

Massachusetts, USA-based biotechnology start-up Anchor Therapeutics has entered into a collaboration…

Anchor TherapeuticsBiotechnologyJohnson & JohnsonLicensingMetabolicsOphthalmicsOrtho-McNeil-JanssenPharmaceutical

Ipsen grants Rhythm exclusive global rights to two metabolic disorder programs for up to $80 million

15-03-2010

Paris, France-based biotechnology firm Ipsen has concluded an agreement with US biotech Rhythm Pharmaceuticals…

BiotechnologyDiabetesGastro-intestinalsLicensingMetabolicsPharmaceutical

Back to top